Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as used in conjunction with a hardware plate system. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation system; Spider cervical plating system; Axle Interspinous Fusion System; Silex Sacroiliac joint fusion system; Xpress minimally invasive pedicle screw system; and Fortex Pedicle screw system. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
IPO Year:
Exchange: AMEX
Website: xtantmedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/5/2023 | $2.00 | Buy | BTIG Research |
Third Quarter Revenue Growth of 12%Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 MillionRepresenting Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024.Third Quarter 2024 Financial HighlightsRevenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year periodGross margin of 58.4% compared to 61.3% for the prior year quarterNet loss of $5.0 mi
BELGRADE, MT / ACCESSWIRE / November 11, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced announced that Sean Browne, CEO and Scott Neils, CFO will be attending the following upcoming conference:Event: 15th Annual Craig-Hallum Alpha Select ConferenceDate: November 19, 2024Location: Sheraton NY Times Square Hotel, New York, NYFormat: 1x1 MeetingsFor more information, please visit: https://www.meetmax.com/sched/event_110237/conference_home.html?bank_access=0&event_id=110237About Xtant Medical Holdings, Inc.Xtant Medical's mission of honoring the gift of donation so that our
BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2024, after the close of the financial markets on Tuesday, November 12, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Tuesday, November 12, 2024 at 4:30 PM ET to review results.Conference Details:Conference Date: Tuesday, November 12, 2024Conference Time: 4:30 PM ETConference dial-in: 888-999-3182International dial-in:
New System Enhances Surgical Efficiency and Provides Versatile Solutions for Complex Spine ProceduresBELGRADE, MT / ACCESSWIRE / September 23, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a leading global medical technology company focused on the treatment of spinal disorders, is excited to announce the launch of the Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries. Now available to surgeons across the United States through Xtant's commercial channels., Cortera enhances surgical workflows while delivering value across a wide spectrum of complex spinal procedures."The Cortera Posterior Fixation System is a significant addi
New Cellular Bone Matrix Designed with Cohesive and Moldable Handling Characteristics BELGRADE, MT / ACCESSWIRE / September 18, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has launched a new addition to its robust product portfolio, OsteoVive Plus, a moldable, viable bone matrix that can be used in a variety of grafting procedures. The graft is now available, to the company's nationwide distribution network of independent agents as well as original equipment manufacturer relationships.OsteoVive Plus Sean Browne, President and CEO of Xtant Medical, stated, "New
BELGRADE, MT / ACCESSWIRE / August 9, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of its previously announced $5.0 million private placement with an existing institutional investor. The Company sold 7,812,500 shares of common stock at a purchase price of $0.64 per share. After deducting fees and other estimated offering expenses, the Company received net proceeds of approximately $4.6 million.The Company expects to use the net proceeds from the private placement for working capital and other general corporate purposes.Craig-Hallum acted as sole placement a
BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with an existing institutional investor to sell shares of its common stock in a private placement. The Company agreed to issue an aggregate of 7,812,500 shares of common stock at a purchase price of $0.64 per share, resulting in gross proceeds of $5.0 million.The Company expects to use the net proceeds from the private placement for working capital and other general corporate purposes. The closing of the private placement is expected to
BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 8, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Friday, August 9, 2024, at 9:00 AM ET to review results.Conference Details:Conference Date: Friday, August 9, 2024Conference Time: 9:00 AM ETConference dial-in: 888-999-3182International dial-in: 848-280-6330Pas
BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024.Second Quarter 2024 Financial HighlightsRevenue of $29.9 million, up 48%, compared to the prior year quarterGross margin of 62.1%, up 50 basis points, compared to the prior year quarterNet loss of $3.9 million compared to $2.2 million in the year ago quarterPositive Adjusted EBITDA; Adjusted EBITDA of $0.5 million compared to $0.1 million in the prior year quarterRecent Business HighlightsRecently launched two new
BELGRADE, MT / ACCESSWIRE / July 25, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will attend the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase being held August 13-15, 2024 at the InterContinental Boston, an IHG Hotel.Sean Browne, President and Chief Executive Officer will present on Wednesday, August 14th at 11:00 a.m. Eastern.A video webcast of the presentation will be available at: https://wsw.com/webcast/canaccord98/xtnt/2523378About Xtan
BTIG Research initiated coverage of Xtant Medical with a rating of Buy and set a new price target of $2.00
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
10-Q - Xtant Medical Holdings, Inc. (0001453593) (Filer)
8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
EFFECT - Xtant Medical Holdings, Inc. (0001453593) (Filer)
424B3 - Xtant Medical Holdings, Inc. (0001453593) (Filer)
EFFECT - Xtant Medical Holdings, Inc. (0001453593) (Filer)
POS AM - Xtant Medical Holdings, Inc. (0001453593) (Filer)
S-3 - Xtant Medical Holdings, Inc. (0001453593) (Filer)
8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
D - Xtant Medical Holdings, Inc. (0001453593) (Filer)
8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
Third Quarter Revenue Growth of 12%Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 MillionRepresenting Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024.Third Quarter 2024 Financial HighlightsRevenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year periodGross margin of 58.4% compared to 61.3% for the prior year quarterNet loss of $5.0 mi
BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2024, after the close of the financial markets on Tuesday, November 12, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Tuesday, November 12, 2024 at 4:30 PM ET to review results.Conference Details:Conference Date: Tuesday, November 12, 2024Conference Time: 4:30 PM ETConference dial-in: 888-999-3182International dial-in:
BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 8, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Friday, August 9, 2024, at 9:00 AM ET to review results.Conference Details:Conference Date: Friday, August 9, 2024Conference Time: 9:00 AM ETConference dial-in: 888-999-3182International dial-in: 848-280-6330Pas
BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024.Second Quarter 2024 Financial HighlightsRevenue of $29.9 million, up 48%, compared to the prior year quarterGross margin of 62.1%, up 50 basis points, compared to the prior year quarterNet loss of $3.9 million compared to $2.2 million in the year ago quarterPositive Adjusted EBITDA; Adjusted EBITDA of $0.5 million compared to $0.1 million in the prior year quarterRecent Business HighlightsRecently launched two new
Expects Revenue for Full Year 2024 of $116 Million to $120 MillionBELGRADE, MT / ACCESSWIRE / May 15, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2024.First Quarter 2024 Financial HighlightsRevenue of $27.9 million, up 55%, compared to the prior year quarterGross margin of 62.1%, up 340 basis points, compared to the prior year quarterNet loss of $4.4 million compared to $2.1 million in the year ago quarterPositive Adjusted EBITDA; Adjusted EBITDA of $0.1 million compared to an Adjusted EBITDA loss of
BELGRADE, MO / ACCESSWIRE / May 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2024, after the close of the financial markets on Wednesday, May 15, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Wednesday, May 15 at 4:30 PM ET to review results.Conference Details:Conference Date: Wednesday, May 15, 2024Conference Time: 4:30 PM ETConference dial-in: 877-545-0523International dial-in: 973-528-0016Passcode: 69
Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont., April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2023. "2023 was a transformative year for Xtant Medical. We achieved record annual revenues of $91.3 million, up 58% year-over-year, on which we generated organic growth of 15% compared to the prior year," said Sean Browne, President and CEO of Xtant Medical. "Additionally, we successfully integrated three separate busines
BELGRADE, Mont., March 21, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2023, before the open of the financial markets on Monday, April 1, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, April 1 at 9:00 AM ET to review results. Conference Details:Conference Date: Monday, April 1, 2024 - 9:00 AM ETConference dial-in: 877-407-6184International dial-in: 201-389-08
BELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2023. "Driven by strong organic growth of 18%, and contributions from our recent acquisitions, we achieved record third quarter revenue of $25 million, an increase of 73% year-over-year, and raised our 2023 revenue guidance range for the second consecutive quarter," said Sean Browne, President and CEO of Xtant Medical. "I am extremely proud of our team's efforts integrating Surgalign's hardware and biologic
BELGRADE, Mont., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, before the open of the financial markets on Thursday, November 9, 2023. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Thursday, November 9 at 9:00 AM ET to review results. Conference Call Details:Conference Call Date: Thursday, November 9, 2023 - 9:00 AM ETConference Call dial-in: 877-407-6184International dial
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
BELGRADE, Mont., May 18, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Lori Mitchell-Keller to the Company's Board of Directors effective May 16, 2023. Ms. Mitchell-Keller will serve as a member of the Compensation and Audit Committees of the Board of Directors. "We are pleased to welcome Lori to our Board, marking another high-quality independent member addition," said Stavros G. Vizirgianakis, Chairman of Xtant's Board of Directors. "Her deep operations, information technologies, and marketing expertise will be of significant va
BELGRADE, Mont., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Mark Schallenberger as Chief Operations Officer, effective January 16, 2023. "We are thrilled to have Mark rejoin the team as we reinvent Xtant," said Sean Browne, President and Chief Executive Officer of Xtant Medical. "In this newly created role, Mark will drive the modernization of our production, lead the optimization of our processes and operations, and support the diversification and development of new product lines. We look forward to Mark's contributio
BELGRADE, Mont., May 02, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Scott Neils as Chief Financial Officer, effective June 1, 2022. "Scott's success and experience during his tenure at Xtant, including his recent position as interim Chief Financial Officer, makes him an invaluable member of our team," said Sean Browne, President and Chief Executive Officer of Xtant Medical. "Scott's continued contributions will be instrumental as we execute on our growth strategy and deliver on our mission of ‘honoring the gift of donation.'"
BELGRADE, Mont., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Scott Neils as Interim Chief Financial Officer succeeding Greg Jensen, the Company's current Vice President, Finance and Chief Financial Officer, effective January 3, 2022. "We are excited to announce this well deserved promotion for Scott. His demonstrated ability to oversee the Company's finance and accounting operations in his current role as the Company's Controller and his depth of experience in accounting will continue to be a great benefit to Xtant Me
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
Gainers Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 69.6% to $0.77 during Friday's pre-market session. The company's market cap stands at $14.5 million. Adaptimmune Therapeutics (NASDAQ:ADAP) shares moved upwards by 40.59% to $1.42. The market value of their outstanding shares is at $362.8 million. Bionomics (NASDAQ:BNOX) shares moved upwards by 29.56% to $1.28. The market value of their outstanding shares is at $13.6 million. Innovative Eyewear (NASDAQ:LUCY) shares moved upwards by 27.84% to $1.01. The market value of their outstanding shares is at $17.6 million. Xtant Medical Hldgs (AMEX:XTNT) stock moved upwards by 20.97% to $0.9. The market value of their outstandi
BTIG analyst Ryan Zimmerman maintains Xtant Medical Hldgs (AMEX:XTNT) with a Buy and raises the price target from $2 to $3.
Xtant Medical Hldgs (AMEX:XTNT) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by 200 percent. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $27.873 million which beat the analyst consensus estimate of $25.750 million by 8.24 percent. This is a 55.34 percent increase over sales of $17.943 million the same period last year.
- SEC Filing
Xtant Medical Hldgs (AMEX:XTNT) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $28.11 million which beat the analyst consensus estimate of $26.55 million by 5.87 percent. This is a 84.07 percent increase over sales of $15.27 million the same period last year.
BTIG analyst Ryan Zimmerman initiates coverage on Xtant Medical Hldgs (AMEX:XTNT) with a Buy rating and announces Price Target of $2.
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
SC 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
SC 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
SC 13D - Xtant Medical Holdings, Inc. (0001453593) (Subject)
SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
SC 13G - Xtant Medical Holdings, Inc. (0001453593) (Subject)
SC 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)